Treatment of Age-Related Lung Abnormalities Using Estrogen and/or Retinoids
Section: For Industry
Categories: "Respiratory Diseases"
Reference #: 2001-028
OTC Contact: Sharon E. Prisco, M.S., J.D. (Directory Information | Send a Message)
Description
The present invention is directed to methods of treating an age-related loss of lung function. The invention describes use of an estrogen and/or retinoid that specifically bind to Retinoid-Acid- Receptor (RAR).
Applications
- Treating pulmonary diseases such as COPD, asthma, and coronary artery disease
- Treating the age-related loss of alveoli or gas-exchange.
- Diagnostic tool to identify genetic or acquired defect involving RAR function.
Advantages
Stage of Development
Studies demonstrate that postnatal administration of retinoic acid increases the number of alveoli in rats.Relevant Publications
"Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice." Massaro et al; Am J Physiol Lung Cell Mol Physiol. (2004). Dec; 287(6):L1154-9
"Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats," Massaro et al, Am. J. Physiol. (1996)., 270, L305-L310
INVENTORS: Donald Massaro, and Gloria De Carlo Massaro
Patent Status
U.S Patent Application # 10/513,136 entitled “Treatment of Age-Related Lung Abnormalities Using Estrogen and/or Retinoids” filed on June 1, 2005.
